questionsmedicales.fr
Maladies du système nerveux
Maladies du système nerveux central
Encéphalopathies
Épilepsie
Syndromes épileptiques
Épilepsies myocloniques
Épilepsies myocloniques : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques : Questions médicales les plus fréquentes",
"headline": "Épilepsies myocloniques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Épilepsies myocloniques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-27",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndromes épileptiques",
"url": "https://questionsmedicales.fr/mesh/D000073376",
"about": {
"@type": "MedicalCondition",
"name": "Syndromes épileptiques",
"code": {
"@type": "MedicalCode",
"code": "D000073376",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Épilepsies myocloniques progressives",
"alternateName": "Myoclonic Epilepsies, Progressive",
"url": "https://questionsmedicales.fr/mesh/D020191",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques progressives",
"code": {
"@type": "MedicalCode",
"code": "D020191",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.650"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Épilepsie myoclonique juvénile",
"alternateName": "Myoclonic Epilepsy, Juvenile",
"url": "https://questionsmedicales.fr/mesh/D020190",
"about": {
"@type": "MedicalCondition",
"name": "Épilepsie myoclonique juvénile",
"code": {
"@type": "MedicalCode",
"code": "D020190",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C10.228.140.490.493.063.670"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Épilepsies myocloniques",
"alternateName": "Epilepsies, Myoclonic",
"code": {
"@type": "MedicalCode",
"code": "D004831",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pasquale Striano",
"url": "https://questionsmedicales.fr/author/Pasquale%20Striano",
"affiliation": {
"@type": "Organization",
"name": "IRCCS Istituto \"Giannina Gaslini\", Genova, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genova, Italy."
}
},
{
"@type": "Person",
"name": "Marte Syvertsen",
"url": "https://questionsmedicales.fr/author/Marte%20Syvertsen",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
},
{
"@type": "Person",
"name": "Deb K Pal",
"url": "https://questionsmedicales.fr/author/Deb%20K%20Pal",
"affiliation": {
"@type": "Organization",
"name": "Department of Basic & Clinical Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK."
}
},
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Jeanette Koht",
"url": "https://questionsmedicales.fr/author/Jeanette%20Koht",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Drammen Hospital, Vestre Viken Health Trust, Oslo, Norway."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A Probe-Free Occupancy Assay to Assess a Targeted Covalent Inhibitor of Receptor Tyrosine-Protein Kinase erbB-2.",
"datePublished": "2024-08-01",
"url": "https://questionsmedicales.fr/article/39144565",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acsptsci.4c00326"
}
},
{
"@type": "ScholarlyArticle",
"name": "Casein kinase 1 controls the shuttling of epidermal growth factor receptor and estrogen receptor in endometrial carcinoma induced by breast cancer hormonal therapy: Relevance of GPER1/Src.",
"datePublished": "2023-05-29",
"url": "https://questionsmedicales.fr/article/37257767",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.cellsig.2023.110733"
}
},
{
"@type": "ScholarlyArticle",
"name": "Fast Growing Furious Races for Targeting Fibroblast Growth Factor Receptors.",
"datePublished": "2022-11-07",
"url": "https://questionsmedicales.fr/article/36380730",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.14348/molcells.2022.0146"
}
},
{
"@type": "ScholarlyArticle",
"name": "Novel parameter for cancer chemosensitivity to fibroblast growth factor receptor inhibitors.",
"datePublished": "2022-08-30",
"url": "https://questionsmedicales.fr/article/35950366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/cas.15523"
}
},
{
"@type": "ScholarlyArticle",
"name": "Epidermal growth factor receptor cascade prioritizes the maximization of signal transduction.",
"datePublished": "2022-10-10",
"url": "https://questionsmedicales.fr/article/36216834",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-20663-0"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies du système nerveux",
"item": "https://questionsmedicales.fr/mesh/D009422"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies du système nerveux central",
"item": "https://questionsmedicales.fr/mesh/D002493"
},
{
"@type": "ListItem",
"position": 4,
"name": "Encéphalopathies",
"item": "https://questionsmedicales.fr/mesh/D001927"
},
{
"@type": "ListItem",
"position": 5,
"name": "Épilepsie",
"item": "https://questionsmedicales.fr/mesh/D004827"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndromes épileptiques",
"item": "https://questionsmedicales.fr/mesh/D000073376"
},
{
"@type": "ListItem",
"position": 7,
"name": "Épilepsies myocloniques",
"item": "https://questionsmedicales.fr/mesh/D004831"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Épilepsies myocloniques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Épilepsies myocloniques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Épilepsies myocloniques",
"description": "Comment diagnostiquer une épilepsie myoclonique ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent une épilepsie myoclonique ?\nL'épilepsie myoclonique est-elle héréditaire ?\nQuel rôle joue l'EEG dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Épilepsies myocloniques",
"description": "Quels sont les symptômes principaux ?\nLes myoclonies sont-elles douloureuses ?\nPeut-on avoir des crises sans myoclonies ?\nLes symptômes varient-ils d'une personne à l'autre ?\nLes crises peuvent-elles survenir la nuit ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Épilepsies myocloniques",
"description": "Peut-on prévenir les crises myocloniques ?\nQuels déclencheurs sont à éviter ?\nL'éducation est-elle importante pour la prévention ?\nLe suivi médical est-il essentiel ?\nLes activités physiques sont-elles sûres ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Épilepsies myocloniques",
"description": "Quels médicaments sont utilisés pour traiter ?\nY a-t-il des traitements non médicamenteux ?\nComment évaluer l'efficacité du traitement ?\nLes traitements sont-ils à vie ?\nQuels effets secondaires des médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Épilepsies myocloniques",
"description": "Quelles complications peuvent survenir ?\nL'épilepsie myoclonique peut-elle affecter la vie quotidienne ?\nY a-t-il un risque accru de dépression ?\nLes crises peuvent-elles entraîner des accidents ?\nComment gérer les complications psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Épilepsies myocloniques",
"description": "Quels sont les facteurs de risque connus ?\nL'âge influence-t-il le risque d'épilepsie myoclonique ?\nLes troubles neurologiques augmentent-ils le risque ?\nLe stress est-il un facteur de risque ?\nLes infections cérébrales sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D004831?mesh_terms=ErbB+Receptors&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une épilepsie myoclonique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical, l'examen neurologique et l'EEG."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG, l'IRM cérébrale et des tests sanguins peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une épilepsie myoclonique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des secousses musculaires rapides, souvent sans perte de conscience, sont typiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique est-elle héréditaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines formes peuvent être héréditaires, nécessitant une évaluation familiale."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'EEG dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'EEG aide à détecter les anomalies électriques typiques des épilepsies myocloniques."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des myoclonies, des crises généralisées et parfois des absences."
}
},
{
"@type": "Question",
"name": "Les myoclonies sont-elles douloureuses ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les myoclonies ne sont généralement pas douloureuses, mais peuvent être gênantes."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des crises sans myoclonies ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines personnes peuvent avoir des crises généralisées sans myoclonies."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la fréquence des symptômes peuvent varier considérablement."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles survenir la nuit ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des crises myocloniques peuvent survenir pendant le sommeil."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les crises myocloniques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un traitement adéquat et l'évitement des déclencheurs."
}
},
{
"@type": "Question",
"name": "Quels déclencheurs sont à éviter ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress, la fatigue, et la consommation d'alcool peuvent déclencher des crises."
}
},
{
"@type": "Question",
"name": "L'éducation est-elle importante pour la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'éducation sur la maladie aide les patients à mieux gérer leur condition."
}
},
{
"@type": "Question",
"name": "Le suivi médical est-il essentiel ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'ajuster le traitement et de surveiller les symptômes."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines activités peuvent être sûres, mais il faut éviter les sports à risque."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anticonvulsivants comme le valproate et le lamotrigine sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des approches comme la thérapie comportementale et la diététique peuvent aider."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des crises et les effets secondaires."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent, le traitement est à long terme, mais certains peuvent réduire ou arrêter."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, vertiges et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des blessures dues aux crises et des troubles psychologiques."
}
},
{
"@type": "Question",
"name": "L'épilepsie myoclonique peut-elle affecter la vie quotidienne ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut impacter la vie sociale, professionnelle et la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de dépression ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes épileptiques ont un risque plus élevé de dépression et d'anxiété."
}
},
{
"@type": "Question",
"name": "Les crises peuvent-elles entraîner des accidents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les crises peuvent provoquer des accidents, notamment lors de la conduite."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications psychologiques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un soutien psychologique et des thérapies adaptées peuvent aider à gérer ces complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque connus ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, les traumatismes crâniens et certaines infections sont des facteurs."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'épilepsie myoclonique ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'épilepsie myoclonique peut débuter à tout âge, mais souvent dans l'enfance ou l'adolescence."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, d'autres troubles neurologiques peuvent augmenter le risque d'épilepsie myoclonique."
}
},
{
"@type": "Question",
"name": "Le stress est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut déclencher des crises chez les personnes prédisposées."
}
},
{
"@type": "Question",
"name": "Les infections cérébrales sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme la méningite, peuvent augmenter le risque d'épilepsie."
}
}
]
}
]
}
Establishing target engagement is fundamental to effective target-based drug development. It paves the way for efficient medicinal chemistry design and definitive answers about target validation in th...
Casein kinase 1 plays a crucial role in carcinogenesis. 4-Hydroxytamoxifen (4-OHT), which is widely used to treat breast cancer, often leads to the development of endometrial carcinoma with poor progn...
Targeting fibroblast growth factor receptors (FGFRs) has been slow compared to other targeted cancer therapies for receptor tyrosine kinases, such as epidermal growth factor receptors. The low efficac...
Fibroblast growth factor receptor inhibitors (FGFRi) were introduced into clinical trials on several cancer types and found to be particularly efficacious on urothelial cancer and cholangiocarcinoma. ...
Many studies have been performed to quantify cell signaling. Cell signaling molecules are phosphorylated in response to extracellular stimuli, with the phosphorylation sequence forming a signal cascad...
The epidermal growth factor receptor (EGFR) is a central regulator of cell physiology that is stimulated by multiple distinct ligands. Although ligands bind to EGFR while the receptor is exposed on th...
Glioblastoma (GBM) is the most common central nervous system tumor and is associated with poor outcomes. There have been no significant improvements in GBM mortality in recent decades. ER-α36 is a var...
To evaluate the anti-tumour activity and safety of anti-programmed death receptor-1 (PD-1) antibody plus epidermal growth factor receptor blockade combined with platinum-based chemotherapy (PEP) as fi...
We conducted a retrospective review of 17 patients with stage IV PSCC undergoing first-line PEP at Sun Yat-sen University Cancer Center between January 2018 and September 2021. Clinical responses were...
Of 17 patients who received first-line PEP, 13 were observed to have partial responses. Twelve patients subsequently received consolidated surgery. Nine of these achieved pN0 status, of whom six with ...
Anti-PD-1 antibody plus epidermal growth factor receptor blockade and platinum-based chemotherapy showed promising anti-tumour activity, acceptable toxicity, and satisfying long-term survival for stag...
Aberrant activation of the epidermal growth factor receptor (EGFR) by mutations has been implicated in a variety of human cancers. Elucidation of the structure of the full-length receptor is essential...
Epithelial membrane protein 3 (EMP3) is an N-glycosylated tetraspanin with a putative trafficking function. It is highly expressed in isocitrate dehydrogenase-wild-type glioblastoma (IDH-wt GBM), and ...